Marine-Derived Anticancer Compounds and their Clinical Status

Area of Science:

• Marine natural products
• Pharmacological activities
• Drug discovery

Background:

• Marine ecosystems are rich sources of structurally diverse natural compounds.
• Marine-derived molecules show significant promise as anticancer agents.
• These compounds target tumor cell proliferation, apoptosis, and the tumor microenvironment.

Purpose of the Study:

• Review recent advances (2020-2025) in marine-derived compounds for cancer therapy.
• Highlight structural diversity, biological activity, and clinical trial status.
• Emphasize discovery, preclinical evaluation, and clinical development.

Main Methods:

• Systematic literature search across major scientific databases (PubMed, Scopus, etc.) and clinical trial registries.
• Keywords included "marine natural products," "anticancer activity," "clinical trials," and "FDA-approved marine drugs."
• Focused on studies published between 2020 and 2025, extracting cell line activity data.

Main Results:

• Several marine compounds (alkaloids, peptides, polyketides) demonstrate potent anticancer activity in preclinical models.
• FDA-approved marine drugs include trabectedin, eribulin, plitidepsin, and lurbinectedin.
• Numerous marine compounds are currently in clinical trials, showing therapeutic promise.

Conclusions:

• Marine-derived compounds possess significant anticancer potential due to unique structures and mechanisms.
• Recent studies confirm efficacy in targeting tumor growth and overcoming resistance.
• Future research should focus on clinical trials and scalable production for marine compounds in cancer therapy.